ArticleHuman vaccines & immunotherapeutics2025
Social media insights on the introduction of RSV immunoprophylaxis in Italy.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Mapping risk communication practices in public health emergencies: a scoping review and comparison with Italian regional pandemic plans.BMC public health · 2026Article
- Impact of Respiratory Viral Codetections on RSV Disease Burden in Young Children in Primary Care.Influenza and other respiratory viruses · 2026Article
- Review
- Impact of Nirsevimab on bronchiolities in pediatric primary care in Lazio Region: an observational study.Italian journal of pediatrics · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of new immunoprophylaxis strategies against respiratory syncytial virus (RSV), such as maternal vaccination and the administration of monoclonal antibodies to newborns, presents both opportunities and challenges in terms of public understanding and acceptance. Monitoring online discussions can offer timely insights into perceptions of these interventions. We conducted a social media monitoring activity in Italy from September 2024 to January 2025, using the Pulsar platform to analyze posts on X and Facebook, complemented by manual analysis of comments on Instagram and TikTok. We examined content related to RSV prevention, focusing on stance, recurring narratives, and specific questions or doubts. Most content showed a neutral or supportive stance toward RSV immunoprophylaxis, with many users expressing awareness of RSV risk and interest in accessing the monoclonal antibody. However, recurring information needs emerged around eligibility, access, safety, and the distinction between different prevention options. Criticism toward the government was also observed, linked to initial decisions that limited free provision of the antibody to certain regions, later reversed, which left perceptions of inequality. Only a limited proportion of posts contained clear misinformation or disinformation. These results were consistent with recent surveys in other countries showing high parental acceptance of similar interventions. These findings underscore the need to address specific information gaps and ensure clear, consistent communication to support trust in RSV immunoprophylaxis. Proactive efforts will be important to reinforce the generally positive attitudes observed and to mitigate concerns that could affect the acceptance of new preventive measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.